Wedbush Has Optimistic Outlook of KNSA Q1 Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities researchers at Wedbush boosted their Q1 2025 EPS estimates for shares of Kiniksa Pharmaceuticals in a research report issued to clients and investors on Monday, January 13th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.10 per share for the quarter, up from their prior estimate of $0.09. Wedbush has a “Outperform” rating and a $34.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.15 EPS and FY2025 earnings at $0.56 EPS.

KNSA has been the topic of several other reports. Evercore ISI boosted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Stock Up 2.6 %

Shares of KNSA stock opened at $18.82 on Thursday. The business’s fifty day moving average price is $20.94 and its 200 day moving average price is $23.27. Kiniksa Pharmaceuticals has a 1-year low of $16.56 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.20) EPS.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now owns 88,975 shares in the company, valued at $1,622,904. This represents a 13.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,092 shares of company stock valued at $471,609 in the last 90 days. 54.57% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors have recently modified their holdings of KNSA. Braidwell LP boosted its position in Kiniksa Pharmaceuticals by 40.6% during the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after acquiring an additional 836,210 shares during the last quarter. FMR LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 36,925.0% during the third quarter. FMR LLC now owns 696,810 shares of the company’s stock worth $17,413,000 after purchasing an additional 694,928 shares during the last quarter. Millennium Management LLC grew its position in shares of Kiniksa Pharmaceuticals by 159.8% in the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock valued at $11,612,000 after purchasing an additional 382,539 shares during the period. Jane Street Group LLC increased its stake in Kiniksa Pharmaceuticals by 1,064.4% in the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock valued at $8,624,000 after purchasing an additional 315,456 shares during the last quarter. Finally, Rubric Capital Management LP lifted its position in Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after buying an additional 223,094 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.